WPP
PTCT icon

Whalerock Point Partners’s PTC Therapeutics PTCT Stock Holding History

Whalerock Point Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19,225
Closed -$1.17M – 152
2015
Q1 		$1.17M Hold
19,225
– – 0.48% 40
2014
Q4 		$995K Buy
19,225
+2,370
+14% +$104K 0.42% 44
2014
Q3 		$741K Buy
+16,855
New +$527K 0.33% 56

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Whalerock Point Partners's PTCT Position: Q2 2015 in Review

Whalerock Point Partners sold out of PTC Therapeutics (PTCT) in Q2 2015, closing a stake of 19,225 shares — an estimated $1.17M sold.

Whalerock Point Partners first reported a position in PTCT in Q3 2014 and held it in 3 quarters. The position peaked at $1.17M in Q1 2015. 155 funds tracked by Wall St. Rank hold PTCT as of Q2 2015.

  • Whalerock Point Partners reported no remaining PTC Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Whalerock Point Partners sold 19,225 PTC Therapeutics shares in Q2 2015, an estimated $1.17M.
  • Whalerock Point Partners first reported a position in PTC Therapeutics in Q3 2014 and held it in 3 quarters.
  • Whalerock Point Partners's PTC Therapeutics position peaked at $1.17M in Q1 2015.
  • 155 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2015.

Based on Whalerock Point Partners's 13F filing for Q2 2015, filed 28 Jul 2015.